Reproductive Hormones and Immune Cell Metabolism: Mechanisms, Clinical Implications, and Emerging Evidence

Abstract

This review examines the complex interplay between reproductive hormones and immune cell metabolism, emphasizing mechanistic insights, clinical relevance, and implications for disease management. We synthesize recent PubMed-indexed evidence to detail how estrogens, progesterone, and androgens modulate immune responses via metabolic reprogramming of lymphocytes, macrophages, and dendritic cells. Understanding these interactions has profound implications for autoimmune disease prevalence, infection susceptibility, and therapeutic strategies, particularly in gender-specific contexts. The review also explores current guideline recommendations and highlights areas for future research.

Introduction

Reproductive hormones, including estrogens, progesterone, and androgens, are central regulators of physiological processes across the lifespan. Beyond their classical roles in reproductive health, accumulating evidence underscores their profound effects on immune function. Immune cell metabolism—encompassing glycolysis, oxidative phosphorylation, and lipid metabolism—has emerged as a critical determinant of immune cell fate and function. The intersection of reproductive endocrinology and immunometabolism is a burgeoning field with significant clinical ramifications, especially considering sex-based disparities in autoimmune diseases, infection outcomes, and responses to immunomodulatory therapies.

Epidemiology / Disease Burden

Sex-based differences in immune-mediated diseases are well-documented. Autoimmune conditions such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and multiple sclerosis (MS) disproportionately affect women, implicating reproductive hormones in disease susceptibility. Conversely, infectious disease outcomes often demonstrate heightened severity in males, suggesting divergent immunomodulatory effects of androgens and estrogens. The burden of these diseases is significant, contributing to morbidity, mortality, and healthcare expenditures globally. Understanding the hormonal regulation of immune metabolism provides a framework for explaining these epidemiological patterns and targeting interventions.

Pathophysiology

Reproductive hormones influence immune cell metabolism through receptor-mediated signaling pathways. Estrogens, acting via estrogen receptors (ERα and ERβ), upregulate glycolytic enzymes in T cells, promoting pro-inflammatory Th17 differentiation while constraining Treg development. Progesterone generally exerts immunosuppressive effects, favoring oxidative phosphorylation and supporting Treg-mediated tolerance. Androgens modulate macrophage metabolism, skewing toward anti-inflammatory M2 phenotypes and restraining glycolysis-driven inflammatory responses. These metabolic shifts impact cytokine production, cell proliferation, and apoptosis, ultimately shaping immune surveillance, tolerance, and autoimmunity. Importantly, hormone fluctuations—such as those occurring during the menstrual cycle, pregnancy, and menopause—dynamically alter immune cell bioenergetics, influencing disease activity and infection risk.

Risk Factors

Several intrinsic and extrinsic factors modulate the impact of reproductive hormones on immune metabolism. Genetic polymorphisms affecting hormone receptors or metabolic enzymes can alter susceptibility to immune dysregulation. Life stage (puberty, pregnancy, menopause), exogenous hormone use (oral contraceptives, hormone replacement therapy), and comorbid metabolic conditions (obesity, diabetes) further influence hormonal effects on immunity. Environmental exposures, including endocrine disruptors, may also perturb this axis, with potential long-term immunological consequences.

Clinical Features

The clinical manifestations of hormone-immune interactions are diverse. In autoimmune diseases, disease onset and flares often correlate with hormonal transitions—such as postpartum exacerbations in SLE. Infections may display sex-specific clinical courses, with males exhibiting increased severity in viral illnesses like COVID-19 and influenza. Hormonal therapies can modulate symptomatology, with estrogen replacement sometimes ameliorating autoimmune symptoms but increasing thrombotic risk. Awareness of these patterns informs clinical vigilance and management decisions.

Diagnosis

Diagnostic evaluation should consider hormonal status in patients presenting with immune-mediated or infectious diseases. Hormone assays (estradiol, progesterone, testosterone, FSH, LH) provide insight into endocrine status, particularly in reproductive-aged or peri-menopausal women. Immunophenotyping and metabolic profiling of leukocytes—using flow cytometry and metabolomic techniques—can elucidate functional alterations linked to hormonal states. Integration of clinical, hormonal, and immunological data supports precision diagnosis and risk stratification.

Treatment & Management

Management strategies must account for the bidirectional effects of reproductive hormones and immune cell metabolism. Hormonal therapies (e.g., estrogen supplementation, androgen blockade) may be indicated in specific contexts but require careful risk-benefit assessment. Immunometabolic modulators, such as metformin and mTOR inhibitors, exhibit potential for correcting hormone-driven immune dysregulation. Lifestyle interventions targeting metabolic health—such as diet, exercise, and weight management—can synergistically improve immune homeostasis, particularly in patients with comorbid metabolic syndrome or PCOS.

Recent Advances / Emerging Therapies

Recent research has elucidated novel molecular targets linking reproductive hormones to immunometabolism. Selective estrogen receptor modulators (SERMs) are being investigated for their ability to fine-tune immune responses in autoimmune and infectious diseases. Advances in single-cell transcriptomics and metabolomics are uncovering sex-specific immune signatures, enabling the development of personalized therapies. Immunotherapy protocols are increasingly considering hormonal status and sex as variables influencing efficacy and toxicity, especially in oncology and transplantation.

Guideline Recommendations

Contemporary guidelines highlight the importance of sex and hormonal status in the assessment and management of immune-mediated and infectious diseases. The American College of Rheumatology and European League Against Rheumatism recommend consideration of hormonal influences when evaluating disease activity in conditions like SLE and RA. Infectious disease societies advocate for sex-stratified analysis in clinical trials and vaccine studies. Endocrine guidelines emphasize monitoring and managing metabolic comorbidities in patients receiving hormonal therapies. Interdisciplinary collaboration between endocrinologists, immunologists, and primary care providers is essential for optimal patient care.

Conclusion

The intricate crosstalk between reproductive hormones and immune cell metabolism underlies key sex differences in disease susceptibility, progression, and therapeutic response. Mechanistic insights into hormone-driven metabolic reprogramming of immune cells are reshaping our understanding of autoimmunity, infection, and immunotherapy. Clinicians should integrate hormonal status and metabolic health into diagnostic, preventive, and therapeutic strategies. Ongoing research promises to refine personalized medicine approaches, with the potential to improve outcomes for diverse patient populations.